Trials / Completed
CompletedNCT01564758
Post Marketing Surveillance Study on Linezolid
Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 99 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Linezolid is safe for adult Filipino patients diagnosed with gram positive infections.
Detailed description
The subjects were identified after the physician decided to prescribed the drug to the subject.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linezolid | 1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days 2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days 3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2012-03-28
- Last updated
- 2012-08-06
- Results posted
- 2012-08-06
Source: ClinicalTrials.gov record NCT01564758. Inclusion in this directory is not an endorsement.